The influence of Mexidol on the improvement of cognitive status and quality parameters as part of the complex therapy of patients with chronic heart failure of the II - III functional class

Author:
TOLKACHEVA V.V., KARAPETYAN L.V., KHUTSISHVILI N.I., GALOCHKIN S.A., KAZAKHMEDOV E.R., KOBALAVA Zh.D.

FGAOU in Russian University of Friendship of Peoples named after Patrice Lumumba, Moscow, Russia

Place of publication:
CARDIOLOGY AND CARDIOVASCULAR SURGERY, 2023, Vol. 16, No. 4

Abstract:
Objective. To evaluate the effect of Mexidol as part of combination therapy for heart failure for 10 weeks on cognitive status, quality of life parameters, asthenic syndrome, and anxiety level in patients with CHF functional class II-III (according to the NYHA classification). Material and methods. The open randomized study included 60 comorbid patients with coronary artery disease (CAD) and stable chronic heart failure (CHF) with cognitive impairment (CI) ≤24 points according to the Montreal Cognitive Assessment (MoCA). The mean age of patients was 73.4±8.6 years, 53% were male, the mean ejection fraction was 43.5±10.6%. Thirty patients were included in the standard therapy group for CHF with the additional prescription of Mexidol (500 mg intravenously by drip once a day for 14 days, then 250 mg 3 times a day for 8 weeks) and 30 patients in the standard therapy group. At baseline and at the end of the study, the effect of therapy on the cognitive status of patients was assessed using the Montreal Cognitive Assessment (MoCA), the level of anxiety according to the Beck Anxiety Inventory, the severity and dynamics of asthenic syndrome according to the subjective asthenia assessment scale (MFI-20), the health profile according to the EQ-5D-5L questionnaire and the quality of life parameters according to the Minnesota Heart Facts Questionnaire (MLHFQ), Kansas City Cardiomyopathy Questionnaire (KCCQ) and the SF36 "Quality of Life Assessment" questionnaire. Results. In patients receiving Mexidol in addition to standard therapy, a significant improvement in cognitive function by 21%, a decrease in anxiety by 38% and in the severity of asthenic syndrome by 12%, an improvement in general well-being according to the EQ-5D-5L questionnaire by 25%, as well as quality of life according to the Minnesota Heart Questionnaire by 48% and according to the Kansas Heart Questionnaire by 39% were observed. Conclusion. Mexidol, when added to standard therapy in patients with CHF functional class II-III, significantly improves cognitive status, quality of life parameters, reduces the severity of asthenic syndrome and anxiety levels. Key words: heart failure, cognitive status, quality of life, Mexidol.